In 2018, CONCORD-3 updated long-term surveillance of cancer survival trends worldwide. In this monograph, we conducted further analyses and examined trends in net survival using the Japanese data during 2000-14.
Sixteen population-based cancer registries in Japan contributed data to CONCORD-3 with anonymized individual records on 2 237 861 patients diagnosed with one of 15 adult cancers (15-99 years), and brain tumors and hematological malignancies in children (0-14 years). Five-year net survival was estimated with the Pohar Perme estimator and age-standardized with International Cancer Survival Standard weights. We estimated survival for three calendar periods, by age group, sex, anatomic site or morphology, and by stage at diagnosis.
Five-year net survival improved between 2000-04 and 2010-14 for several cancers, including brain tumors (27.9%-46.3%), ovarian cancer (35.5%-46.3%), stomach cancer (50.5%-60.3%), lymphoid malignancies (47.5%-57.3%), myeloid malignancies (24.8%-33.3%), and esophageal cancer (27.7%-36.0%). Breast cancer, childhood lymphoma, and prostate cancer showed consistently high or improving survival (85.9%-93.0%). In contrast, survival for melanoma remained unchanged. Net survival was low for pancreatic cancer (6.9%-8.3%). Among selected countries, survival was higher in Japan for esophageal (36.0%), liver (30.1%), and lung cancers (32.9%). Survival for melanoma, hematologic malignancies, and childhood cancers was lower in Japan than in Western countries.
Net survival in Japan improved substantially for several cancers, but survival for pancreatic cancer remained low. International collaboration is crucial to accelerate the development of effective cancer control strategies.
Japanese journal of clinical oncology. 2026 Mar 20 [Epub]
Hiromi Sugiyama, Veronica Di Carlo, Melissa Matz, Izumi Oki, Akiko Shibata, Kayo Nakata, Mari Kajiwara Saito, Masashi Matsuzaka, Marisa Nishio, Isao Oze, Kaname Watanabe, Rina Tanaka, Laureline Gatellier, Isao Yoshida, Hidemi Ito, Norihiro Teramoto, Natsumi Yamashita, Yasuharu Kaizaki, Fumitaka Moki, Katsuki Kurosawa, Yuji Nemoto, Hiroto Narimatsu, Seiki Kanemura, Isao Miyashiro, Daisuke Mori, Shin Fujita, Tomohiro Matsuda, Michel P Coleman, Claudia Allemani
Department of Epidemiology, Radiation Effects Research Foundation, 5-2 Hijiyama Park, Minami-ku, Hiroshima City, Hiroshima 732-0815, Japan., Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom., Department of Health Sciences, Saitama Prefectural University, 820 Sannomiya, Koshigaya-shi, Saitama 343-8540, Japan., Yamagata Prefectural Central Hospital, 1800 Oaza-Aoyanagi, Yamagata City, Yamagata 990-2214, Japan., Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka city, Osaka 541-8567, Japan., Hirosaki University Hospital, 53, Honcho, Hirosaki, Aomori 036-8563, Japan., Division of Prevention, National Cancer Center Institute for Cancer Control, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan., Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan., Kanagawa Cancer Center Research Institute, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan., Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, Aomori 036-8562, Japan., Division of International Health Policy Research, National Cancer Center Institute for Cancer Control, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan., Department of Hematologic Oncology, NHO Shikoku Cancer Center, Minamiumenomoto-cho, Matsuyama, Ehime 791-0280, Japan., Division of Cancer Prevention and Epidemiology, Center for Cancer Research, Shikoku Cancer Center, Minamiumenomoto-cho, Matsuyama, Ehime 791-0280, Japan., Fukui Prefectural Hospital, 2-8-1 Yotsui, Fukui-city, Fukui 910-8526, Japan., Gunma Health Foundation, 16-1 Horinoshita-machi, Maebashi, Gumma 371-0005, Japan., Ibaraki Prefectural Office, 978-6, Kasahara-cho, Mito, Ibaraki 310-8555, Japan., Ibaraki Pharmaceutical Association Inspection Center, 978-47, Kasahara-cho, Mito, Ibaraki 310-0852, Japan., Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiote, Natori, Miyagi 981-1293, Japan., Saga-ken Medical Centre Koseikan, 400 Nakabaru, Kasemachi, Saga 840-8571, Japan., Tochigi Cancer Center, 4-9-13, Yohnan, Utsunomiya, Tochigi 320-0834, Japan.